Clinical Trials Browser

Phase 2 × Withdrawn × Tauopathies × Clear all

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction